HC Wainwright Rates Nuvectis Pharma (NVCT) buy, $39 Price Target
Analyst Joseph Pantginis maintains a buy rating on Nuvectis Pharma with a $39 target, a 51.75% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Nuvectis Pharma, Inc. ($NVCT) "buy" with a $39 price target on June 22, 2026.
Since the rating, $NVCT is up 72.6% after 1 week, up 16.7% after 1 month and up 12.5% to date (from the $16.53 close on Jun 22, 2026).
NVCT
Nuvectis Pharma, Inc.
Key Points
- HC Wainwright's Joseph Pantginis reiterated a buy rating on Nuvectis Pharma, Inc. (NVCT) with a $39 price target on June 22, 2026.
- HC Wainwright's $39 price target implies 51.75% upside from Nuvectis Pharma, Inc.'s ($NVCT) current $25.70 share price.
- Nuvectis Pharma is a clinical-stage biotech company with a market cap of $366.6 million and a 52-week range of $5.55 to $14.16.
- Recent insider buying included Kenneth Hoberman and others, each acquiring 35,000 shares on June 11, 2026.
Get $NVCT trade alerts by text
We text you when insiders, Congress or big funds trade $NVCT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Nuvectis Pharma, Inc. alert may contain errors. Disclosures
HC Wainwright & Co.'s analyst Joseph Pantginis has reiterated a buy rating on Nuvectis Pharma, Inc. (NasdaqCM: NVCT) as of June 22, 2026. The firm set a price target of $39 for the biopharmaceutical company, which is currently developing precision medicines for oncology.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Nuvectis Pharma
BlackRock, Inc. trimmed its holdings by 18,364 shares, ending with 764,441 shares valued at about $5.91 million. Vanguard Capital Management LLC opened a new position with 659,879 shares worth $5.10 million. Iridian Asset Management LLC/CT increased its stake by 65,437 shares to hold 651,757 shares valued at approximately $5.04 million. Occam Crest Management LP added 27,147 shares, totaling 407,147 shares valued at $3.15 million. Geode Capital Management, LLC grew its position by 20,081 shares to 384,105 shares, worth about $2.97 million.
Nuvectis Pharma, Inc. Stock Up 16.8%
Shares of Nuvectis Pharma traded near $13.54 on Monday. The company has a market cap of $366.6 million and is not currently profitable, as indicated by its negative forward P/E ratio of -14.4. The stock's 52-week low is $5.55, while its high is $14.16. The 50-day moving average is $9.89, and the 200-day moving average is $7.99. Nuvectis has a current ratio of 2.27 and a quick ratio of 2.25.
$NVCT price target
Nuvectis Pharma, Inc. daily closes and this analyst's $39 target. Not advice.
Insider Buying and Selling at Nuvectis Pharma, Inc.
On June 11, 2026, several insiders, including Kenneth Hoberman, James Oliviero III, Matthew Kaplan, and Juan Sanchez, each purchased 35,000 shares. Additionally, Shay Shemesh, the Chief Development and Operations Officer, and Ron Bentsur, the Chairman and CEO, each acquired 150,000 shares on January 6, 2026.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. maintained its buy rating on Nuvectis Pharma with a $39 price target. Overall, the company has a strong buy consensus with a mean target price of $17.4 based on five analyst opinions.
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for treating serious oncology conditions. Based in Fort Lee, New Jersey, the company is working on NXP900, a drug candidate targeting solid tumors. Founded in 2020, Nuvectis is led by CEO Ron Bentsur and employs 12 people.
Bottom Line
HC Wainwright's reiteration of a buy rating signals confidence in Nuvectis Pharma's prospects, with a significant price target set at $39. As a clinical-stage company, Nuvectis is developing innovative treatments in oncology, drawing interest from institutional investors and analysts alike. Investors should note that analyst ratings are forward-looking and reflect expectations based on current data.
Related Filing Alerts
Source: HC Wainwright's rating change on $NVCT (Jun 22, 2026). Written by software, not financial advice. How we make alerts